Overview of plasma variants detected by NGS.
MUTANT, DISEASE PROGRESSION
The total number, distribution and origin of variants detected by serial liquid biopsy analyses are shown for 45 patients with at least two serial liquid biopsies performed. A WBC DNA-informed approach allowed for classification of plasma variants by cellular origin and revealed that 17% of the plasma variants detected (14/82 variants) could be attributed to clonal hematopoiesis mutations. Frequently mutated genes included The maximal mutant allele fraction (maxMAF) of tumor-derived plasma mutations was tracked from the pre-treatment timepoint (C1D1) to on-therapy timepoints (C2D1 and C3D1), with maxMAF clearance signifying molecular response (mR), whereas persistence of maxMAF indicated molecular disease progression (mPD) (Supplementary Table 